Summary
Updated Aug 31, 2026
Claude Nicaise is Director of Gain Therapeutics, Inc. (GANX). 4 SEC Form 4 filings on record going back to 2025, most recently on 17 July 2026.
Recent Transactions
3Every recent SEC Form 4 transaction Claude Nicaise has reported, most recent first.
Trading Pattern
InsiderAlpha's records for Claude Nicaise go back to 2025: 4 primary Form 4 filings, an average of 2.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Claude Nicaise files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ian Michael Estepan - $294K of SRPT open-market activity in the last 12 months
- Stephen Mayo - $123K of SRPT open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Claude Nicaise?
Claude Nicaise is a corporate insider, tracked as Director of Gain Therapeutics, Inc. (GANX). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Claude Nicaise submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of Claude Nicaise's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Claude Nicaise and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial